Study Title: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Gourdin, Theodore, at gourdith@musc.edu.Study Coordinator, Tucker, Renee, at tuckerr@musc.edu.Trial opened at the following institutions: Medical University of South Carolina